Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pulmonx Corp.

Latest From Pulmonx Corp.

Pulmonx's FDA Nod: First To US Market With Endobronchial Valve System

Pulmonx announced US FDA approval of its Zephyr endobronchial valve system for treating severe emphysema patients. This makes it the first minimally invasive device to be approved in the US for treating severe emphysema, a severe form of chronic obstructive pulmonary disease.

Approvals Respiratory

Market Intel: Promising Data At ATS2018 Inflate Hopes For Endobronchial Valves And New Device-Based COPD Therapies

Chronic obstructive pulmonary disease (COPD) is a widespread, progressive lung disease for which pulmonologists in the US have had few new treatment options available outside the standard pharmacological therapies, lung rehabilitation and high-risk lung volume reduction surgery. Now emerging technologies, in particular, endobronchial valves, which aim to shrink hyperinflated lungs in severe emphysema patients, could soon become the first minimally invasive treatment option available in the US. New study results, presented at this year's annual American Thoracic Society International Conference in San Diego, helped built momentum among US-based clinicians to extend upon their therapeutic arsenal for patients for devices that have already been widely used in Europe. This article discusses study findings presented at ATS, including a new cost-comparison analysis for treating COPD patients at home using non-invasive ventilation and oxygen therapy. We'll also discuss the latest innovative technologies for COPD patients presented at ATS and provide insights from leading experts on factors they think will drive treatment options forward.

Respiratory Commercial

BTG Heads To Panel Next Month For Emphysema Device

A PMA for the PneumRx ELEVAIR endobronchial coil system will be considered by a US FDA advisory panel in June, but there will likely be some questions about the data.

Advisory Committees Approvals

Pulmonx's Zephyr Data Bring NICE Thumbs-Up For Endobronchial Valves

The UK’s National Institute for Health and Care Excellence (NICE) is now recommending insertion of endobronchial valves used to treat severe emphysema, and the Interventional Procedures Advisory Committee that wrote the recommendations points out that most of the support for this procedure comes from trials of Pulmonx' Zephyr "duckbill" endobronchial valve.

Respiratory United Kingdom
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Pulmonx Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pulmonx Corp.
  • Senior Management
  • Glen French, Pres. & CEO
    Derrick Sung, PhD, CFO
    Beran Rose, VP, Mktg. & Bus. Dev.
    Sri Radhakrishnan, VP, R&D
  • Contact Info
  • Pulmonx Corp.
    Phone: (650) 364-0400
    700 Chesapeake Dr.
    Redwood City, CA 94063